Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Behind the Study: ONC201, TRAIL, and Breast Cancer

Oncotarget

July 5, 2021
Founding Oncotarget Editorial Board Member, Dr. Wafik S. El-Deiry, and recent MD/PhD graduate of Temple University, Dr. Marie D. Ralff, discuss their 2020 paper: “TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.” continue reading »

Trending With Impact: ONC201 Induces Apoptosis in Breast Cancer

Oncotarget

July 1, 2021
A novel therapeutic combination converts anti-proliferative effects in breast cancer cells to pro-apoptotic. continue reading »

Amino Acid Transporter May Be Promising Anti-Cancer Target

Oncotarget

June 23, 2021
Researchers used CRISPR-Cas9 and a number of other biological analyses to investigate the oncogenetic tendency of human LAT1. continue reading »

Table of Contents: Oncotarget’s Volume 12, Issue #13

Oncotarget

June 22, 2021
Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 13. continue reading »

Trending With Impact: Low-Dose Chemo Inhibits Resistant Breast Cancer

Oncotarget

June 17, 2021
In this trending study, researchers assessed the efficacy of low-dose 6-mercaptopurine and 5-azacitidine to inhibit highly resistant triple-negative breast cancer cells. continue reading »